Katarzyna Czajkowska

Dr. Katarzyna Czajkowska

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in International Urology and Nephrology
Verified
Journal Article
Open access
PDF file
Mateusz CzajkowskiMateusz Czajkowski
Mateusz Czajkowski
PWPiotr Wierzbicki
Piotr Wierzbicki
AKAnna Kotulak-Chrząszcz
Anna Kotulak-Chrząszcz
KCKatarzyna Czajkowska
Katarzyna Czajkowska
MVMarika Daria Verma
Marika Daria Verma
MMMarcin Matuszewski
Marcin Matuszewski
Purpose: To assess the expression of selected cytokines in penile lichen sclerosus (PLS) and associate them with the occurrence of micro-incontinence (MI) in different stages of PLS. Methods: The skin biopsies from 49 PLS affected, and 13 from nonlesional foreskins (healthy control adult males undergoing circumcision due to phimosis caused by short frenulum) were obtained. All specimens were used for RNA extraction and RT-qPCR. Quantitative assessment of the gene expression of interleukin 1-A (IL-1A), interleukin 1-B (IL-1B), interleukin 1 receptor antagonist (IL-1RN), interleukin 6 (IL-6), transforming growth factor β1 (TGF-β1), and interferon-gamma (INF-γ) was performed. To determinate the presence of MI, the patients were asked about voiding patterns, especially leaking tiny drops of urine from the urethral meatus after urination. Results: IL-1A, IL-6, and INF-γ mRNA levels were approximately 150, 16, and 59 times higher in PLS than in control samples, respectively. The highest IL-1A mRNA levels were observed in early PLS (n = 13), INF-γ in moderate PLS (n = 32), while IL-6 in severe PLS (n = 4). MI was noted in 45 PLS patients vs. 0 in control (p < 0.0001). IL-1A and IL-6 vs control ratios were concentration (ca.) 400 and 30 times higher, respectively, in MI PLS samples than in PLS without MI. Conclusion: Occlusion and irritating urine effect are associated with the clinical progression of penile LS with increased mRNA expression of IL-1A, INF-γ, and IL-6 pro-inflammatory cytokines in the foreskin.

9 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MLMarta Labon
Marta Labon
KCKatarzyna Czajkowska
Katarzyna Czajkowska
MMMarcin Matuszewski
Marcin Matuszewski
Mateusz CzajkowskiMateusz Czajkowski
Mateusz Czajkowski
Background/Objectives: Extramammary Paget disease (EMPD) is a rare, slow-growing intraepithelial malignancy arising in apocrine gland-bearing skin, most commonly in the anogenital region. Although often confined to the epidermis, EMPD may be associated with synchronous or underlying malignancies and can progress to invasive disease, making early recognition and compre- hensive staging crucial. Methods: We review current knowledge on the epidemiology, molecular pathogenesis, diagnostic work-up and treatment of EMPD with a particular focus on male genital involvement, and illustrate key clinical issues with two cases of penoscrotal EMPD treated in our center. Clinically, EMPD typically presents as chronic erythematous, pruritic plaques that are frequently misdiagnosed as benign dermatoses, leading to diagnostic delays. Results: Histopathology with immunohistochemistry remains the diagnostic gold standard and guides the search for associated internal malignancies. Wide local excision and Mohs micrographic surgery are the mainstays of treatment, but recurrence is common owing to subclinical extension. Non-surgical modalities—including photodynamic therapy, topical imiquimod, radiotherapy and, in advanced disease, systemic chemotherapy, HER2 targeted agents and immune checkpoint inhibitors—provide additional options in selected patients. Conclusions: A multidisciplinary, biomarker driven approach is essential to individualize management and improve long-term outcomes in this challenging disease.

30 October 2019 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
ARAlicja Rustowska‐Rogowska
Alicja Rustowska‐Rogowska
JGJolanta Gleń
Jolanta Gleń
TJTomasz Jarząbek
Tomasz Jarząbek
WRWojciech Rogowski
Wojciech Rogowski
KRKrzysztof Rębała
Krzysztof Rębała
MSMałgorzata Sokołowska‐Wojdyło
Małgorzata Sokołowska‐Wojdyło

20 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
Mateusz CzajkowskiMateusz Czajkowski
Mateusz Czajkowski
KCKatarzyna Czajkowska
Katarzyna Czajkowska
PWPiotr Wierzbicki
Piotr Wierzbicki
AKAnna Kotulak-Chrząszcz
Anna Kotulak-Chrząszcz
MSMalgorzata Sokolowska-Wojdylo
Malgorzata Sokolowska-Wojdylo
MMMarcin Matuszewski
Marcin Matuszewski
Zoon balanitis (ZB) is a mild and chronic inflammatory dermatosis that mostly affects uncircumcised men of middle and old age. The etiology of this disease remains unknown. Moreover, some authors have questioned the presence of this type of balanitis. Our study aimed to assess the expression of proinflammatory cytokines in ZB and demonstrate the presence of a characteristic expression pattern, different from that reported in the literature for penile lichen sclerosus(LS) and penile cancer. Skin biopsies from four foreskins affected by Zoon’s balanitis with surrounding morphologically unchanged skin and 13 from nonlesional foreskins (healthy control adult males undergoing circumcision) were obtained. RNA was extracted from each biopsy, followed by quantitative assessment of the gene expression of interleukin 1-A(IL-1A), interleukin 1-B(IL-1B),interleukin 1 receptor antagonist(IL-1RN),interleukin 6(IL-6), transforming growth factor β1(TGF-β1), and interferon-gamma(INF-γ). The decreased level of IL-1A mRNA was observed in Zoon’s balanitis in both inflamed and healthy skin compared to control samples. There were no statistically significant differences in other investigated cytokines gene expression between Zoon’s balanitis and the control group. In conclusion, the expression of proinflammatory cytokines was not related to the course of zoon balanitis. Moreover, in the case of IL-1A, we observed the suppression of the immune response.

2 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KCKatarzyna Czajkowska
Katarzyna Czajkowska
Mateusz CzajkowskiMateusz Czajkowski
Mateusz Czajkowski
Roman J. NowickiRoman J. Nowicki
Roman J. Nowicki
MMMarcin Matuszewski
Marcin Matuszewski
MSMalgorzata Sokolowska-Wojdylo
Malgorzata Sokolowska-Wojdylo
Background: Prospective comparative evidence for topical treatment of Zoon’s balanitis is limited. We evaluated early clinical changes during two topical regimens and explored recorded long-term outcomes. Methods: In this single-centre, prospective, open-label, non-randomised study, 37 men with histopathologically confirmed Zoon’s balanitis were allocated by alternation to fluticasone propionate 0.05% (n = 18) or fusidic acid 2% (n = 19) for four weeks. Early assessments used a four-point study Investigator’s Global Assessment (IGA) and symptom visual analogue scales. Additional exploratory comparisons included IGA 0 at week 4. A separate categorical assessment was undertaken in 2026. The study was not registered in a public clinical-trial registry. Results: Mean IGA decreased from 2.17 to 0.67 with fluticasone and from 2.26 to 0.89 with fusidic acid between baseline and week 4. Complete clearance occurred in 8/18 (44.4%) and 6/19 (31.6%) participants, respectively; the absolute difference was 12.9 percentage points (95% confidence interval, −17.1 to 40.1; Fisher’s exact p = 0.50768). Among participants assessable in 2026, recorded remission occurred in 12/16 (75.0%) and 3/15 (20.0%), respectively (unadjusted odds ratio, 12.00; approximate 95% confidence interval, 2.20–65.52; p = 0.00385). These data did not establish uninterrupted or treatment-free remission; missing-outcome sensitivity analyses limited the robustness of the association. Conclusions: Clinical severity improved during both regimens, but comparative equivalence was not established. The association between initial fluticasone allocation and recorded remission in 2026 is hypothesis-generating and requires confirmation in a registered, adequately powered controlled study with standardised long-term assessment.